Genesis Research Group launches free access to EVID AI, its full-spectrum evidence synthesis platform, through 2026
June 24, 2026 | AI, HEOR, Market Access, RWE, evidence, evidence synthesis, genesis, literature reviews, slr
Genesis Research Group today announced that its EVID AI evidence synthesis platform will be available free of charge through 2026 for approved life sciences organizations and eligible researchers. “Run it yourself. Run it with Genesis. Or have Genesis run it for you.”
Genesis Research Group today announced that its EVID AI evidence synthesis platform will be available free of charge through 2026 for approved life sciences organizations and eligible researchers.
Developed in-house by Genesis scientists and refined through two years of real-world application in client evidence work, EVID AI provides a structured environment for conducting evidence synthesis activities, from rapid evidence queries and targeted literature reviews to ongoing literature surveillance and end-to-end systematic reviews.
Designed as a flexible working model, the EVID AI free access program enables teams and individuals to run projects independently, collaborate with Genesis experts, or delegate entirely, depending on their needs.
“Run it yourself. Run it with Genesis. Or have Genesis run it for you.”
A single environment for evidence work
EVID AI brings evidence activities into one place, removing fragmentation across tools and processes, providing teams with a practical way to apply the same structured approaches used in evidence work within a single platform and workflow. It enables teams to:
- Identify and assess relevant literature
- Manage structured review workflows
- Monitor evolving evidence landscapes
- Support decision-making with clearer, more structured outputs
Designed for life sciences decision-making
EVID AI has been built and refined within Genesis’ own work, reflecting evidence synthesis needs across HEOR, RWE, Medical Affairs, and Market Access.
By aligning with real-world workflows, it supports faster, more informed decisions across the product lifecycle, supporting how therapies are evaluated, understood, and ultimately made available to patients.
Access and next steps
Approved users will receive free platform access through 31 December 2026, with optional access to Genesis expertise for protocol design, search strategy, screening, interpretation, and full project delivery.
Expert support remains separate from the platform offer and is provided based on user needs. Interested individuals can request access via the Genesis website.
Request free access at genesisrg.com.
About Genesis Research Group
EVIDENCE. EXPERIENCE. JUDGMENT.
Genesis Research Group is a global life sciences consulting firm specializing in evidence generation, health economics and outcomes research, real-world evidence, market access, pricing strategy, and stakeholder insights. Genesis combines rigorous evidence, deep expertise, and practical judgment to help companies reduce uncertainty and make better decisions across development, launch, access, and commercialization.
This content was provided by Genesis Research Group
Company Details
Latest Content from Genesis Research Group
How does Genesis Research Group ‘Innovate differently’?
New Genesis Research Group CEO David W. Miller explains what we mean when we say we help our life science clients to ‘Innovate differently’ and transform the way they engage…
Envision Analogue – An Introduction
Powered by primary payer market research, Envision is an online platform that provides forward-looking evaluations and comprehensive strategic direction for market access viability after an oncology product has received positive…
World EPA Congress 2024: ‘Shining the light on vaccine market access’ by Genesis Research Group
A presentation with Katrin Nather, PhD, Associate Director, and Tijana Ignjatovic, Executive Director, Genesis Research Group. Contact solutions@genesisrg.com or visit www.genesisrg.com. With more and more innovative vaccines and immunization strategies…
Fit-for-purpose matchmaking webinar: a data selection and RWE approach for both regulatory and HTA audiences
This webinar reviews considerations for the design and data selection for RWE studies, including external control arm studies, to meet regulatory and HTA needs. Regulators and agencies responsible for market…
Genesis Research Group RWD / HTA / regulatory / ECA webinar on 15 Feb: reserve your place!
On 15 February 2024, Carole Longson and Allie Sosinsky of Genesis Research Group, a leading global provider of tech-enabled real-world evidence, market access, and HEOR solutions, will present a webinar…